H.C. Wainwright maintained a positive stance on Arcturus Therapeutics (NASDAQ:ARCT) shares, reiterating a Buy rating and a price target of $63. Currently trading at $16.97, the stock has significant ...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...
Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a ...
In the assessment of 12-month price targets, analysts unveil insights for Arcturus Therapeutics, presenting an average target ...
Oil and gas companies Arcturus Corp. and Aschere Energy LLC, along with founder Leon Ali Parvizian, must pay more than $10 ...
BTIG initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $41 price target Arcturus is a commercial-stage biotechnology ...
The co-development and project finance agreement will accelerate deployment of Skyven's cutting-edge, "decarbonizing" ...
BTIG Research began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a ...
Skyven Technologies, a leader in emissions-free industrial steam, and Kyotherm, a renowned financier of renewable thermal ...
Equities research analysts at Leerink Partnrs upped their FY2024 EPS estimates for shares of Arcturus Therapeutics in a note ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback